NCT07364656Not yet recruiting
Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 196 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- IRCCS Policlinico S. Donato
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT07364656
What you commit to
- Study type: Interventional
- Planned participants: 196
- From 1 Jan 2026 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of high-dose immunosuppressive drugs or other experimental treatments that could interfere with the assessment of study endpoints
Other illness
- Clinically significant cardiovascular diseases (atrial fibrillation, congestive heart failure, cardiomyopathies, or inherited arrhythmic syndromes)
- Known autoimmune diseases or immunodeficiencies
Who the study is looking for
- Age ≥ 18 years
- Patients with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic
- Patients already receiving first-line therapy with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic
- Signed informed consent
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Policlinico San donato Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.